Keywords: Novartis, secukinumab, psoriasis, Amgen, Enbrel, etanercept
Article | 08 July 2013
Swiss drug major Novartis (NOVN: VX) has announced results from a Phase III psoriasis study which showed the superiority of …
Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.